"
Team:Potsdam Bioware
From 2011.igem.org
(Difference between revisions)
(→Safety and Security Assessment) |
|||
| Line 5: | Line 5: | ||
<p> | <p> | ||
| - | + | <h2>Project</h2> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | <h2> | + | |
<p style="text-align:justify;">One key task of biopharmaceuticals is the binding and blocking of deregulated proteins. Towards this goal, we mutate and select microviridins, which are tricyclic depsipeptides from cyanobacteria. They are small but stable due to their post-translational side-chain crosslinking. Microviridins have a high potential for therapy as they can block disease-relevant proteases. Yet, the possibilities of cyclic peptides are largely untapped since genetic systems for optimization are not well established. Thus, we developed synthetic systems for the mutation, selection and production of such peptides. We use the 6.5 kb microviridin (mdn) gene cluster cloned in E. coli plasmids, established random mutagenesis and generated focused libraries of microviridins. For selection against a panel of proteases, we are applying and testing phage display, and we are constructing a novel in-vivo selection device, which links protease blocking to antibiotic resistance. Our systems, including the 6.5 kb cluster, adhere to the BioBrick standards. | <p style="text-align:justify;">One key task of biopharmaceuticals is the binding and blocking of deregulated proteins. Towards this goal, we mutate and select microviridins, which are tricyclic depsipeptides from cyanobacteria. They are small but stable due to their post-translational side-chain crosslinking. Microviridins have a high potential for therapy as they can block disease-relevant proteases. Yet, the possibilities of cyclic peptides are largely untapped since genetic systems for optimization are not well established. Thus, we developed synthetic systems for the mutation, selection and production of such peptides. We use the 6.5 kb microviridin (mdn) gene cluster cloned in E. coli plasmids, established random mutagenesis and generated focused libraries of microviridins. For selection against a panel of proteases, we are applying and testing phage display, and we are constructing a novel in-vivo selection device, which links protease blocking to antibiotic resistance. Our systems, including the 6.5 kb cluster, adhere to the BioBrick standards. | ||
| Line 18: | Line 14: | ||
</div> | </div> | ||
| - | <!---Box on the upper left: | + | <!---Box on the upper left: Software---> |
<div class="box_home"> | <div class="box_home"> | ||
| - | <h2> | + | <h2>Software</h2> |
<p> | <p> | ||
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Project/Results"><span class="bold">[more]</span></a></p> | Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Project/Results"><span class="bold">[more]</span></a></p> | ||
</div> | </div> | ||
| - | <!---Small box on the right: Team | + | <!---Small box on the right: Team |
<div class="box_long"> | <div class="box_long"> | ||
| Line 33: | Line 29: | ||
<a href="https://2011.igem.org/Team:Potsdam_Bioware/Team/Team_2011"><span class="bold">[more]</span></a></p> | <a href="https://2011.igem.org/Team:Potsdam_Bioware/Team/Team_2011"><span class="bold">[more]</span></a></p> | ||
</div> | </div> | ||
| + | |||
| + | --> | ||
<!--- News Ticker ---> | <!--- News Ticker ---> | ||
<div class="box_long box_long_news news_ticker"> | <div class="box_long box_long_news news_ticker"> | ||
| - | <a href="https://2011.igem.org/Team:Potsdam_Bioware/NoteBook/Statistics" style="z-index:20;position:relative;"><h2> | + | <a href="https://2011.igem.org/Team:Potsdam_Bioware/NoteBook/Statistics" style="z-index:20;position:relative;"><h2>Team</h2></a> |
<ul id="news" class="newsticker"> | <ul id="news" class="newsticker"> | ||
<li><div class="news"> | <li><div class="news"> | ||
| Line 61: | Line 59: | ||
</div> | </div> | ||
| - | <!---Box on the lower left: | + | <!---Box on the lower left: Human Practice---> |
<div class="box_home_small"> | <div class="box_home_small"> | ||
| - | <h2> | + | <h2>Human Practice</h2></a> |
<p class="standard">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Safety_ethics"><span class="bold">[more]</span></a></p> | <p class="standard">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Safety_ethics"><span class="bold">[more]</span></a></p> | ||
</div> | </div> | ||
| Line 74: | Line 72: | ||
</div> | </div> | ||
| - | <!---Box on the lower right: | + | <!---Box on the lower right: Modelling---> |
<div class="box_home_small"> | <div class="box_home_small"> | ||
| - | <h2> | + | <h2>Modelling</h2></a> |
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. | Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. | ||
<a href="https://2011.igem.org/Team:Potsdam_Bioware/software"><span class="bold">[more]</span></a></p> | <a href="https://2011.igem.org/Team:Potsdam_Bioware/software"><span class="bold">[more]</span></a></p> | ||
| Line 82: | Line 80: | ||
</div> | </div> | ||
<div class="clearfix"></div> | <div class="clearfix"></div> | ||
| - | + | <!-- | |
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
===Labjournal=== | ===Labjournal=== | ||
<li>[[labjournal_may| May]] | <li>[[labjournal_may| May]] | ||
| Line 98: | Line 91: | ||
<li>[[labjournal_september|September]] | <li>[[labjournal_september|September]] | ||
| + | --> | ||
| + | </html> | ||
| + | |||
<html><center><div id="clustrmaps-widget"></div><script type="text/javascript">var _clustrmaps = {'url' : 'https://2011.igem.org/Team:Potsdam_Bioware', 'user' : 910340, 'server' : '2', 'id' : 'clustrmaps-widget', 'version' : 1, 'date' : '2011-07-15', 'lang' : 'en', 'corners' : 'square' };(function (){ var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = 'http://www2.clustrmaps.com/counter/map.js'; var x = document.getElementsByTagName('script')[0]; x.parentNode.insertBefore(s, x);})();</script><noscript><a href="http://www2.clustrmaps.com/user/239de404"><img src="http://www2.clustrmaps.com/stats/maps-no_clusters/2011.igem.org-Team-Potsdam_Bioware-thumb.jpg" alt="Locations of visitors to this page" /></a></noscript><center></html> | <html><center><div id="clustrmaps-widget"></div><script type="text/javascript">var _clustrmaps = {'url' : 'https://2011.igem.org/Team:Potsdam_Bioware', 'user' : 910340, 'server' : '2', 'id' : 'clustrmaps-widget', 'version' : 1, 'date' : '2011-07-15', 'lang' : 'en', 'corners' : 'square' };(function (){ var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = 'http://www2.clustrmaps.com/counter/map.js'; var x = document.getElementsByTagName('script')[0]; x.parentNode.insertBefore(s, x);})();</script><noscript><a href="http://www2.clustrmaps.com/user/239de404"><img src="http://www2.clustrmaps.com/stats/maps-no_clusters/2011.igem.org-Team-Potsdam_Bioware-thumb.jpg" alt="Locations of visitors to this page" /></a></noscript><center></html> | ||
Revision as of 12:50, 18 September 2011
Project
One key task of biopharmaceuticals is the binding and blocking of deregulated proteins. Towards this goal, we mutate and select microviridins, which are tricyclic depsipeptides from cyanobacteria. They are small but stable due to their post-translational side-chain crosslinking. Microviridins have a high potential for therapy as they can block disease-relevant proteases. Yet, the possibilities of cyclic peptides are largely untapped since genetic systems for optimization are not well established. Thus, we developed synthetic systems for the mutation, selection and production of such peptides. We use the 6.5 kb microviridin (mdn) gene cluster cloned in E. coli plasmids, established random mutagenesis and generated focused libraries of microviridins. For selection against a panel of proteases, we are applying and testing phage display, and we are constructing a novel in-vivo selection device, which links protease blocking to antibiotic resistance. Our systems, including the 6.5 kb cluster, adhere to the BioBrick standards.
Software
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren. [more]
Team
Lorem Ipsum 1:
1Lorem Ipsum 2:
2
BioBricks
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.[more]
Human Practice
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. [more]
Labjournal
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.[more]
Modelling
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. [more]
